AZP-3601 PTH Compound for Hypoparathyroidism Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypoparathyroidism, such as Natpara™ and TransCon™PTH, fail to maintain steady blood calcium levels, normalize urinary calcium excretion, and preserve bone integrity, leading to persistent symptoms and increased risk of fractures and kidney disease.
Innovation Solution
Administration of a PTH compound with an amino acid sequence as set forth in SEQ ID NO: 10, such as AZP-3601, which maintains or improves bone integrity, normalizes urine calcium levels, and maintains steady state blood calcium levels without the need for oral calcium and activated vitamin D supplementation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments (calcium supplements and activated vitamin D) are used to maintain serum calcium levels, then serum calcium concentration can be controlled, but urinary calcium excretion increases leading to nephrocalcinosis and kidney disease
Solution Approach 1:
The patent changes the fundamental treatment parameter from calcium/vitamin D supplementation to PTH hormone replacement. This shifts the mechanism from passive calcium supply to active hormonal regulation, thereby controlling both serum calcium levels and urinary calcium excretion through physiological PTH action on renal calcium reabsorption
Solution Approach 2:
PTH acts as an intermediary hormone that mediates between calcium supplementation and renal calcium handling. The PTH compound regulates calcium reabsorption in the kidneys, preventing hypercalciuria while maintaining normocalcemia, thus eliminating the harmful effect of direct calcium supplementation
2Quantity of substance
If PTH compounds (Natpara™ and TransCon™PTH) are administered to control hypocalcemia, then serum calcium levels improve, but bone integrity deteriorates increasing fracture risk
Solution Approach 1:
The patent modifies the PTH compound parameters (amino acid sequence, molecular structure) to create a novel analog that differs from natural PTH(1-34) and TransCon™PTH. This structural parameter change results in altered biological activity that preserves bone integrity while maintaining calcium homeostasis, avoiding the bone loss side effect of existing PTH treatments
Solution Approach 2:
The novel PTH compound exhibits differential action on different tissues: it effectively raises serum calcium levels while having a neutral or protective effect on bone tissue. This local quality differentiation allows the drug to treat hypocalcemia without the detrimental bone effects seen with other PTH compounds
3Object-generated harmful factors
If PTH compounds are administered to normalize urinary calcium, then renal function is protected, but serum calcium control becomes unstable
Solution Approach 1:
By changing the molecular parameters of the PTH compound (amino acid substitutions in the sequence), the patent creates a variant with optimized pharmacological properties. This parameter modification achieves a better balance between renal calcium reabsorption effects and serum calcium stabilization, providing both normalized urinary calcium and stable serum calcium control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
AZP-3601 effectively maintains normal serum calcium levels, normalizes urinary calcium excretion, and preserves bone integrity, reducing the risk of fractures and kidney disease, while allowing for the titration off of standard of care treatments.
Implementation Method 1
Signaling is modulated by the PTH receptor at multiple distal sites, resulting in increased absorption of dietary calcium in the gut, increased reabsorption of calcium into the blood prior to excretion by the kidneys, and release of calcium from the mineral-rich deposits of the bone matrix
Data Source
AI summary
The present technology generally relates to a method for management and/or treatment of hypoparathyroidism (HP) in a subject. The method comprises administering a dose of a PTH compound to the subject, wherein the PTH compound has an amino acid sequence as set forth in SEQ ID NO: 10; and wherein administration of the PTH compound maintains or improves bone integrity.